Lyra Therapeutics reports Q3 EPS ($3.38), consensus ($4.07)

Reports Q3 revenue $25,000, consensus $154,250. “We are now focused on putting all the components in place for a new, confirmatory Phase 3 clinical trial to make progress toward a New Drug Application (“NDA”) for LYR-210 as a six-month treatment for CRS patients without nasal polyps,” said Maria Palasis, President and CEO, Lyra Therapeutics (LYRA). “We are excited to move forward with our business strategy and to advance LYR-210 as a novel therapeutic option for millions of CRS patients who fail current medical therapy.”